Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £39.11B | 64.9x | GBX 54,398.37 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £32.43B | -987.8x | -12 | GBX 53,518 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £9.94B | 19.1x | 1.35 | GBX 15,612.62 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.57B | 101.1x | -1.44 | GBX 3,473.19 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £5.80B | -44.7x | 3.05 | GBX 8,131.40 | 7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.96B | 17.6x | 0.13 | GBX 3,526.71 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Geron Corp | London | Healthcare | Biotechnology & Medical Research | £1.45B | -9.4x | -1.62 | GBX 238.96 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.19B | 151.7x | -2.11 | GBX 1,810 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.2% Upside | Upgrade to Pro+ | |
Intellia Therapeutics | London | Healthcare | Biotechnology & Medical Research | £855.14M | -1.9x | 1.16 | GBX 833.57 | 9.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £433.44M | -2.9x | 0.03 | GBX 409 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £354.34M | -6.2x | 0.07 | GBX 148 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £274.07M | -5.4x | -0.1 | GBX 5.75 | -11.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £218.01M | -1.9x | -0.14 | GBX 481.12 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £173.40M | -5.5x | -0.15 | GBX 47.50 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £168.96M | -4.2x | -1.16 | GBX 150 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £157.89M | 19.5x | -5.84 | GBX 3,025 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £150.46M | -15.9x | 0.29 | GBX 1,175 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hvivo | London | Healthcare | Biotechnology & Medical Research | £126.55M | 7.1x | 0.02 | GBX 18.50 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £110.48M | -2.6x | -0.05 | GBX 851.15 | 11.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £92.45M | -5.6x | 0.22 | GBX 9 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £90.38M | -0.5x | -0.12 | GBX 104.70 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £81.19M | -228.4x | 1.51 | GBX 18.60 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £75.62M | -3.1x | -0.12 | GBX 58.96 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adverum Biotechnologies | London | Healthcare | Biotechnology & Medical Research | £75.09M | -0.8x | -0.02 | GBX 359.64 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £58.13M | -0.4x | -0.02 | GBX 159.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £54.51M | -45.4x | GBX 18.32 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £52.59M | 160.9x | -2.05 | GBX 101.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £49.35M | -13.5x | -0.46 | GBX 15.90 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £43.12M | -12.4x | -1.37 | GBX 18.88 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £37.94M | -0.9x | -0.02 | GBX 313.50 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £36.80M | -1x | 0.02 | GBX 52 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OncoCyte | London | Healthcare | Biotechnology & Medical Research | £28.25M | -0.5x | -0.02 | GBX 171.83 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shield Therapeutics | London | Healthcare | Biotechnology & Medical Research | £26.43M | -0.9x | -0.01 | GBX 3.38 | 18.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £25.50M | -11.1x | -0.57 | GBX 5.15 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synairgen | London | Healthcare | Biotechnology & Medical Research | £24.81M | -0.6x | -0.12 | GBX 2.25 | 15.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sareum | London | Healthcare | Biotechnology & Medical Research | £24.35M | -4.6x | -0.75 | GBX 19.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arecor Therapeutics | London | Healthcare | Biotechnology & Medical Research | £20.58M | -2.7x | -0.29 | GBX 54.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ananda Developments | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £19.13M | -1.8x | 0.18 | GBX 0.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuPharma | London | Healthcare | Biotechnology & Medical Research | £18.78M | -7.3x | -0.27 | GBX 4.51 | -9.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Palatin Technologies | London | Healthcare | Biotechnology & Medical Research | £15.59M | -0.4x | 0.1 | GBX 68.86 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Optibiotix Health | London | Healthcare | Biotechnology & Medical Research | £15.43M | -4.9x | -0.07 | GBX 15.75 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Phaxiam Therapeutics | London | Healthcare | Biotechnology & Medical Research | £15.15M | -0.4x | GBX 151.14 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
MEI Pharma | London | Healthcare | Biotechnology & Medical Research | £15.07M | -0.4x | 0 | GBX 212.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Celyad | London | Healthcare | Biotechnology & Medical Research | £14.76M | -2x | -0.03 | GBX 66.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synlogic | London | Healthcare | Biotechnology & Medical Research | £12.52M | -0.4x | -0.01 | GBX 108.69 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hemogenyx Pharma | London | Healthcare | Biotechnology & Medical Research | £12.44M | -2x | -0.06 | GBX 345 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IXICO | London | Healthcare | Biotechnology & Medical Research | £10.89M | -2.9x | 0.08 | GBX 11.75 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incanthera | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £8.47M | -3.3x | -0 | GBX 0.07 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OpGen | London | Healthcare | Biotechnology & Medical Research | £8.16M | -0.2x | -0.01 | GBX 126.43 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Aeterna Zentaris | London | Healthcare | Biotechnology & Medical Research | £7.93M | -0.2x | 0.02 | GBX 237 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |